Placements

Senior Vice President of Sales and Service

Freeslate, Inc.

We are proud to announce the successful completion of Search Assignment # A43601 for a Senior Vice President of Sales and Service at Freeslate, Inc. Our client is a privately held biotechnology company that designs, develops, and markets proprietary laboratory automation technology that integrates automated workflows for high throughput research. The Company delivers solutions that incorporate scientific insight, industry expertise, powerful hardware, and thoughtfully designed software to solve critical research challenges.

The successful candidate chosen is Mr. Thomas O’Lenic. He has over 20 years of successful sales and marketing management experience in the life sciences scientific instrumentation industry. Most recently he was Senior Vice President and General Manager at MDS AT, Molecular Devices. Prior to that he held positions as Vice President of Sales and Service and Director of Sales and Service at Molecular Devices.

Tom will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Tom and our client.

Corporate Vice President and Chief Financial Officer

Mannkind Corporation

We are proud to announce the successful completion of Search Assignment # A22304 for a Corporate Vice President and Chief Financial Officer at MannKind Corporation. Our publicly held biopharmaceutical client is focused on the development and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, a proprietary inhaled insulin system for the treatment of diabetes, is currently in late stage phase 3 clinical trials in the U.S. and Europe. Our client has raised in excess of one billion dollars from private and public rounds of financing over the last eight years and currently has over 650 employees.

The successful candidate chosen is Mr. Matthew Pfeffer. He has over 25 years of demonstrated financial management experience in the pharmaceutical industry. Most recently, Matt was Senior Vice President and Chief Financial Officer at Vaxgen, with responsibilities for finance, tax, treasury, IT, and facilities. For the previous nine years, he served as CFO for Cell Genesys. Prior to that, he held a variety of financial management positions including roles as Corporate Controller and Manager of Internal Audit and reporting. He began his career at Price Waterhouse.

During the search process, there were a total of 125 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Matt will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Matt and our client.

Vice President of Marketing

Gen-Probe, Inc.

We are proud to announce the successful completion of Search Assignment # A42701 for a Vice President of Marketing at Gen-Probe Incorporated. Our publicly held client is a global leader in the development, manufacture, and marketing of rapid, accurate, and cost effective nucleic acid tests (NATs) used to diagnose human diseases and screen donated human blood. It markets a broad portfolio of products that use the Company’s patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases (STDs), tuberculosis, strep throat, pneumonia, and fungal infections.

The successful candidate chosen is Mr. Frederick Eibel. He has over 20 years of marketing and sales management experience in the diagnostics industry. Most recently, Fritz was Vice President of Genomics and Oncology, Global Product Marketing at Roche Diagnostics, where he held various marketing and sales management positions of increased responsibility such as Vice President of Corporate Accounts, National Director of Corporate Accounts, and International Marketing Manager.

During the search process, there were a total of 53 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Fritz will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Fritz and our client.

President and Chief Executive Officer

Transgenomic, Inc.

We are proud to announce the successful completion of Search Assignment # A23701 for a President and Chief Executive Officer at Transgenomic, Inc. Our publicly held client is developing and commercializing unique instrument systems, reagents, and laboratory testing services to the academic and medical research, clinical, and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis. It currently has an installed base of over 1,200 systems in 35 countries worldwide.

The successful candidate chosen is Mr. Craig Tuttle. He has over 25 years of senior management experience in the diagnostic and biotechnology industries. Most recently, Craig was President and COO of Duke Scientific, a specialty chemistry manufacturer, and led its sale to Fisher Healthcare in 2005. Prior to that, he was President of Applied Biotech, Inc. and General Manager of Seradyn, Inc. where he took the company from loss to profitability in just over one year. Previously he held various senior level management positions of increased responsibility at companies such as Boehringer Mannheim, Bayer Healthcare, and Cetus Corporation.

During the search process, there were a total of 83 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Craig will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Craig and our client.

Vice President of Research and Development

Acrometrix

We are proud to announce the successful completion of Search Assignment # A23601 for a Vice President of Research and Development at Acrometrix, Inc. Our Northern California based client is developing and commercializing innovative standards, run controls, quantification panels, and validation kits for the molecular diagnostics industry. Its products are currently sold worldwide to clinical reference laboratories, hospitals, blood screening centers, and major diagnostics manufacturers for use in infectious disease, oncology, and genetic testing.

The successful candidate chosen is Ralf Schoenbrunner, Ph.D. Previously he spent the past fifteen years with Roche Molecular Systems holding various senior research management positions of increased responsibility. Most recently, Ralf was the Director of Research and Development for the Molecular Diagnostics group where he was responsible for TaqMan assay development programs.

During the search process, there were a total of 68 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Ralf will play a leading role in our client’s future research and new product development programs. We look forward to the continued success of both Ralf and our client.

Senior Manager of Software Development and a Product Marketing Director

Freeslate, Inc.

We are proud to announce the successful completion of multiple search assignments for Freeslate, Inc. A Senior Manager of Software Development and a Product Marketing Director have been recruited for our client that is a privately held biotechnology company that designs, develops, and markets proprietary laboratory automation technology that integrates automated workflows for high throughput research. The Company delivers solutions that incorporate scientific insight, industry expertise, powerful hardware, and thoughtfully designed software to solve critical research challenges.

The successful candidates chosen are Mr. Edward Gavin and Mr. David Yamane respectively. Ed has over 20 years of software development experience in the life sciences industry, with companies such as Dionex, Ciphergen, Caliper Life Sciences, and most recently at Life Technologies, Inc. David has over 20 years of product marketing management experience with companies such as Applied Biosystems, Lion Bioscience, and most recently at Molecular Devices.

Both Ed and David will play leading roles in our client’s future growth and commercialization programs. We look forward to the continued success of both Ed, David, and our client.

Vice President of Sales

Nextbio, Inc.

We are proud to announce the successful completion of Search Assignment # A43301 for a Vice President of Sales at NextBio Corporation. Our client is a privately held company that provides an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. The Company’s platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. This helps to increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries, delivered as a Software service solution.

The successful candidate chosen is Mr. Kevin Cronin. He has over 20 years of successful senior management experience in the medical information systems industry. Most recently, he was the Senior Vice President of Sales at Symyx Technologies. Prior to that he held management positions of increased responsibility for 14 years at MDL Information Systems, a division of Reed Elsevier.

Kevin will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Kevin and our client.

Vice President of Product Development

Diadexus, Inc.

We are proud to announce the successful completion of Search Assignment # A42206 for a Vice President of Product Development at Diadexus, Inc. Our client is a privately held biotechnology company focused on the discovery, development, and commercialization of novel patent protected diagnostic products with high clinical value. Its lead product, the PLAC ^® test, is the only blood test cleared by the FDA as an aid in determining risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

The successful candidate chosen is Gary Hewett. He has over 20 years of demonstrated experience in research, product development, and general management in the biotechnology industry. Most recently, Gary was Director of Research and Development at Berkeley HeartLabs. Previously, he served as Executive Vice President, Operations, Research and Development for Hemosense, Vice President of Development at Optiscan Biomedical, and Vice President and Chief Scientific Officer at Cholestech Corporation, where he was also a company founder. Three of his past companies were successfully acquired by larger biotechnology companies, maximizing shareholder value.

During the search process, there were a total of 110 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Gary will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Gary and our client.

Head of Biomarker Discovery

Siemens Healthcare

We are proud to announce the successful completion of Search Assignment # A42502 for a Head of Biomarker Discovery at Siemens Medical Solutions. Our publicly held client is focused on the discovery, optimization, development, and commercialization of molecular imaging probes that will result in the earlier detection of diseases, resulting in improved disease management.

The successful candidate chosen is Anna Katrin Szardenings, Ph.D. She has over 15 years of demonstrated scientific management experience in the biotechnology industry. Most recently, Katrin was Director of Chemistry at ActivX Biosciences, a subsidiary of Kyorin Pharmaceutical, with responsibilities for leading the internal kinase drug discovery team, which discovered and developed a structurally novel kinase inhibitor for the treatment of diabetes. For the previous eight years, she served in scientific management positions of increased responsibility at Affymax Research Institute.

During the search process, there were a total of 74 candidates screened. Katrin will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Katrin and our client.

Senior Director of Clinical Development

Siemens Healthcare

We are proud to announce the successful completion of Search Assignment # A42501 for a Senior Director of Clinical Development at Siemens Biomarker Research. Our client is a division of Siemens Molecular Imaging and is working on the discovery, optimization, and development of innovative molecular imaging probes that will result in earlier detection of disease, improved disease management, and accelerate the therapy development process.

The successful candidate chosen is James Zhang, M.D. He has over 20 years of clinical development experience in the diagnostic and pharmaceutical industry. Most recently, Jim was Director of Clinical Operations for Bracco Diagnostics. Prior to this he held various positions of increased responsibility at Wyeth Pharmaceuticals and Thomas Jefferson University Hospital.

During the search process, there were a total of 85 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Jim will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Jim and our client.

Executive Vice President of Marketing and Sales

Diadexus, Inc.

We are proud to announce the successful completion of Search Assignment # A42201 for an Executive Vice President of Marketing and Sales at Diadexus, Inc. Our Northern California based client is a privately held biotechnology company focused on the discovery, development, and commercialization of novel, patent protected diagnostic products with high clinical value.

The successful candidate chosen is Mr. Bernard Alfano. He has over 20 years of sales, marketing, and general management experience in the medical field. Most recently he served as Corporate Vice President, President of Diagnostics Business unit at Iris, Inc. where he was instrumental in the company’s turnaround. Prior to this, he was Vice President of Business and Product Development for Oxibio, Inc. where he authored the business plan and raised money through private investors and strategic partners for this start up company. Previously, he held various sales and marketing management positions of increased responsibility at companies like Litmus Concepts, Inc., C.R. Bard, Bard Diagnostics Sciences Division, Syntex, and Syva Company.

During the search process, there were a total of 75 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Mr. Alfano will play a leading role in our client’s future growth and commercialization programs, providing a vital cornerstone for the Company’s future growth and success. We look forward to the continued success of both Bernard and our client.

Vice President and Chief Financial Officer

NewLink Genetics

We are proud to announce the successful completion of Search Assignment # A24201 for a Vice President and Chief Financial Officer at NewLink Genetics Corp. Our privately held biopharmaceutical client is focused on the development of vaccines for lung cancer, melanoma, pancreatic, and prostate cancer. It currently has four vaccine candidates in clinical trials.

The successful candidate chosen is Mr. Gordon Link. He has over 25 years of demonstrated financial management experience in the pharmaceutical industry. For the past fifteen years, Gordon was Senior Vice President and Chief Financial Officer at Tapestry Pharmaceuticals, formerly NaPro BioTherapeutics, with responsibilities for finance, tax, treasury, and business development. Previously, he served as Corporate Controller and Treasurer for Synergen and the Syntex-Synergen joint venture. Earlier in his career, he held a variety of financial management positions including roles as Audit Director at Deloitte & Touche.

During the search process, there were a total of 145 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Gordon will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Gordon and our client.

Vice President of Manufacturing Operations

Diadexus, Inc.

We are proud to announce the successful completion of Search Assignment # A42209 for a Vice President of Manufacturing Operations at Diadexus, Inc. Our client is a privately held biotechnology company engaged in the discovery, development, and commercialization of novel, patent protected diagnostic products with high clinical value. The Company’s lead product, the PLAC^®Test, is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

The successful candidate chosen is Mr. William Picht. He has over 20 years of successful management experience continually driving strong revenue expansion through expert analysis of operational challenges, impeccable management of resources and personnel, and unmatched commitment to meeting business goals. He is a visionary team leader and communicator, proficient in boosting performance expectations, and assembling efficient and highly motivated teams. Bill’s past positions have been at the executive level with Thermo Fisher/Microgenics, Protogene Laboratories, Eclipse Surgical, and Behring Diagnostics/Syva.

Bill will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Bill and our client.

Chief Scientific Officer

Transgenomic, Inc.

We are proud to announce the successful completion of Search Assignment # A23703 for a Chief Scientific Officer at Transgenomic, Inc. Our publicly held client has developed and commercialized unique instrument systems, reagents, and laboratory testing services to the academic, medical research, clinical, and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis. This technology provides a menu of mutation scanning tests for over 700 cancer associated genes and more than 60 validated diagnostic tests for the pharmaceutical and clinical research marketplace worldwide.

The successful candidate chosen is Eric Kaldjian, M.D.. Most recently, Eric served as Executive Director of Medical Sciences at Gene Logic, Inc. where he directed programs in clinical genomics, biomarker discovery, and molecular diagnostics development. Prior to this, he was Exploratory Therapeutic Area Leader, Oncology, for Pfizer Global Research and Development. Previously he held various senior level management positions of increased responsibility at Parke-Davis and Hoffman La Roche.

During the search process, there were a total of 41 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Eric will play a leading role in our client’s future growth and development programs. We look forward to the continued success of both Eric and our client.

Executive Vice President of Product Development and Chief Technical Officer

Diadexus, Inc.

We are proud to announce the successful completion of Search Assignment # A42210 for an Executive Vice President of Product Development and Chief Technical Officer at Diadexus, Inc. Our client is a privately held diagnostics company engaged in the discovery, development, and commercialization of novel, patent protected diagnostic products with high clinical value. The Company’s lead product, the PLAC^®Test, is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

The successful candidate chosen is Emi Zychlinsky, Ph.D. She has over 17 years of successful management experience in various roles of increased responsibility at Hitachi Chemical Diagnostics. Most recently, she served as Vice President of Operations with responsibility for research and development, manufacturing, procurement, regulatory affairs, and quality. She was awarded her Ph.D. from Stanford University, where she was also a postdoctoral scholar.

Emi will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Emi and our client.

Vice President of Quality and Regulatory Affairs

Althea Technologies

We are proud to announce the successful completion of Search Assignment # A24302 for a Vice President of Quality and Regulatory Affairs at Althea Technologies, Inc. Our client is a global provider of a wide range of contract services to the biotechnology and pharmaceutical industry including cGMP manufacturing of recombinant proteins, DNA-based therapeutics, and vaccines from Phase I through to commercial API production, aseptic fill and finish, gene expression analysis for target validation and lead compound selection, custom real-time qPCR, and assay development services.

The successful candidate chosen is Mr. E.J. Brandreth. Most recently, E.J. served as Vice President of Quality at Favrille, Inc., where he directed all Quality Control, Quality Assurance, Validation, and Process Validation programs for five CBER/EMEA product launches. Previously, he held various senior level RA/QA management positions of increased responsibility at BioMarin Pharmaceuticals and Idec Pharmaceuticals, where he contributed to the development and launch of Zevalin^®and Rituxan^®.

During the search process, there were a total of 37 candidates screened, prior to final offer and acceptance. E.J. will play a leading role in our client’s future growth and expansion programs. We look forward to the continued success of both E.J. and our client.

Director of Business Development

Clontech Laboratories, Inc.

We are proud to announce the successful completion of Search Assignment # A20305 for a Director of Business Development at Clontech Laboratories, a member of the Takara Bio Group. Our client is a premier life science research products company engaged in developing, manufacturing, and marketing more than 1800 products that provide the innovative tools to accelerate scientific discovery. The Company’s portfolio of products and services are focused in the areas of cell biology, molecular biology, nucleic acid chemistry, and molecular research.

The successful candidate chosen is Lorna Neilson, Ph.D. She has over 20 years of experience and demonstrated success in leading complex business development and strategic marketing programs in the life science industry with companies such as Life Technologies, Applied Biosystems, Sequenom, and Geneformatics. Lorna is an innovative visionary professional skilled in negotiating licensing and M&A transactions, strategic alliances, and collaborations with partners in the pharmaceutical, diagnostics, biotechnology, and academic environments.

Lorna will play a leading role in our client’s future growth and product commercialization strategies, providing a vital cornerstone for the Company’s future growth and success. We look forward to the continued success of both Lorna and our client.

Vice President of Commercial Operations

Epitomics, Inc.

We are proud to announce the successful completion of Search Assignment # A23005 for a Vice President of Commercial Operations at Epitomics, Inc. Our privately held biotechnology client is developing and commercializing proprietary rabbit monoclonal antibody products and technologies. It introduced an expanded library of antibodies and reagents into the academic and industrial research marketplace last year and has currently developed collaborations for diagnostics and therapeutic applications.

The successful candidate chosen is Mr. Rocco Raduazo. He has over 15 years of sales and marketing management experience in the life science and diagnostic reagents industries. Most recently, Rocco was Senior Director of Global Sales at Applied Biosystems, Inc., where he built and managed a national sales force of significant revenue. Prior to that, he was Vice President of Sales at Biosource International, Inc. where he had full P/L accountability for the life science reagents product lines. Previously he held various sales and marketing management positions of increased responsibility at companies such as Clontech Laboratories, Life Technologies, Inc., and Boehringer Mannheim Corporation.

During the search process, there were a total of 67 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Rocco will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Rocco and our client.

Vice President of Quality Systems

Inova Diagnostics, Inc.

We are proud to announce the successful completion of Search Assignment # A43407 for a Vice President of Quality Systems at Inova Diagnostics, Inc., a division of the Werfen Group. Our client is a recognized worldwide leader in autoimmune disease diagnostics. Since its founding in 1987, the Company has consistently delivered the first commercially available or FDA cleared autoimmune diagnostic tests for a variety of diseases. Their founders were directly involved in the development of autoimmune disease serology, responsible for the first commercially available autoantibody test kits.

The successful candidate chosen is Ms. Ronda Elliot, ASQ CQA, CMQ/OE. She has over 20 years of quality and regulatory experience in the diagnostics industry, with a successful record in management of quality and regulatory functions. Most recently she was Vice President of Quality and Regulatory at Quest Diagnostics where she was responsible for Quality Assurance, Quality Control, Quality Systems, Regulatory Compliance, and Regulatory Affairs. Prior to that, she spent the previous 15 years in various quality and regulatory positions of increased responsibility at Baxter Healthcare, Microgenics, and Boehringer Mannheim.

Ronda will play a leading role in our client’s future growth. We look forward to the continued success of both Ronda and our client.

Chief Executive Officer

Response Biomedical

We are proud to announce the successful completion of Search Assignment # A42801 for a Chief Executive Officer at Response Biomedical Corporation. Our publicly held client is developing and commercializing rapid on-site diagnostic tests for use with its portable instrument platform to both point-of-care and laboratories for early detection of heart attack and congestive heart failure.

The successful candidate chosen is Mr. Wayne Kay. He has over 25 years of senior management experience in the diagnostic industry. Wayne was formerly President and CEO of Quidel Corporation where he designed and managed a strategy responsible for building and sustaining an unprecedented market leadership of rapid influenza testing from 2%-49% market share, while significantly improving the financial performance of the Company. Since leaving Quidel, he served as an executive advisor to the management and Boards of several early stage companies, as well as serving as an executive advisor to Kleiner Perkins Caufield and Byers, one of the most successful blue-chip healthcare venture capital funds in the U.S.

“We are very excited to have attracted such an experienced, proven executive to lead our company,” said Dr. Richard Bastiani, Chairman of Response Biomedical and former Chairman of ID Biomedical. “Wayne has a wealth of experience in POC diagnostics and will play a leading role in our client’s future rapid growth phase.” We look forward to the continued success of both Wayne and our client.

Senior Vice President of U.S. Sales and Global Marketing

Discoverx Corporation

We are proud to announce the successful completion of Search Assignment # A43701 for a Senior Vice President of U.S. Sales and Global Marketing at Discoverx Corporation.

Our client is a recognized worldwide industry leader that develops, manufactures, and commercializes reagents, complete assay kits, and turnkey solutions for the drug discovery, screening, and life science markets. Founded in 2000, Discoverx is a privately held, venture backed company headquartered in California with offices in England, Germany, and France. The Company is dedicated to the development and commercialization of innovative solutions for discovery research.

The successful candidate chosen is Mr. David Martz. He has over 18 years of sales and marketing management experience in the life sciences industry. Most recently he was Vice President of Sales for Qiagen. Prior to that, he was Vice President of Marketing and Sales at SA Biosciences which was acquired by Qiagen. Previously David held positions of increased responsibility with SuperArray, Inc., Roche Diagnostics, Marligen Biosciences, Incyte Genomics, and Clontech Laboratories.

David will play a leading role in our client’s future growth. We look forward to the continued success of both David and our client.

Vice President of Marketing

Plus Diagnostics, Inc.

We are proud to announce the successful completion of Search Assignment # A43102 for a Vice President of Marketing at Plus Diagnostics, Inc. Our client is a privately held biotechnology company that provides a full range of anatomical pathology services including extensive diagnostic procedures and specialist consultations. The Company’s client base includes but is not limited to hospitals, medical centers, physicians, and dentists. They are a CLIA certified cytology, histology, and molecular pathology laboratory, accredited by the College of American Pathologists.

The successful candidate chosen is Ms. Susan Bailey, joining our client after relocating back to California. She has over 18 years of successful management experience in commercial clinical and anatomic pathology laboratories, diagnostics, and biopharmaceuticals. Most recently she was Vice President of Oncology Product Development at Caris Diagnostics. Previously, she was Vice President of Marketing at Genoptix. Prior to that she held management positions of increased responsibility at Impath Laboratories, Specialty Laboratories, Focus Diagnostics, and the Nichols Institute.

Susan will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Susan and our client.

Member of the Board of Directors

Transgenomic, Inc.

We are proud to announce the successful completion of Search Assignment # A23705 for a Member of the Board of Directors at Transgenomic, Inc. Our publicly held client has developed and commercialized unique laboratory testing services, instrument systems, and reagents to the academic, medical research, clinical, and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis in the fields of pharmacogenomics and personalized medicine.

The successful candidate chosen is Mr. Michael McNulty. Presently Mike serves as General Manager of Diagnostics at Agilent Technologies, Inc. where he focuses on leveraging technology platforms in Microarray, Microfluidic, GC, HPLC, GCMS, and LCMS into clinical laboratories. Prior to this, he served in senior marketing, sales, and operational management positions for Berkeley HeartLabs, ThaumDx, SmithKline Beecham, Quest Diagnostics, and Syva Syntex.

Michael will play a leading role in our client’s future growth. We look forward to the continued success of both Michael and our client.

Chief Operating Officer

Neugenesis Corp.

We are proud to announce the successful completion of Search Assignment # A43201 for a Chief Operating Officer at Neugenesis Corp. Our privately held biopharmaceutical client is focused on the discovery, development, and production of improved high-value biotherapeutics more cost effectively through its expertise in protein expression and combinatorial biology.

The successful candidate chosen is Michael Buckley, Ph.D.. He has over 20 years of demonstrated operational management experience in the pharmaceutical industry. Most recently, Michael was Vice President of Manufacturing at Genitope Corporation, with responsibilities for all manufacturing operations. Prior to this, he served as Vice President, Bexxar^® Operations for Corixa Corporation, with responsibilities for the global commercial and clinical supply chain operations.

During the search process, there were a total of 106 candidates screened, prior to final offer and acceptance. Mike will play a leading role in our client’s future growth and product commercialization programs. We look forward to the continued success of both Mike and our client.

Vice President of Sales

Avanir Pharmaceuticals, Inc.

We are proud to announce the successful completion of Search Assignment # A22403 for a Vice President of Sales at Avanir Pharmaceuticals, Inc. Our San Diego based client has a commercialized approved product on the market and has received FDA acceptance under priority review for its New Drug Application for Neurodex^TM, its lead drug candidate indicated for the treatment of involuntary emotional expression disorder.

The successful candidate chosen is Mr. Matthew Ruth. Matt is an experienced sales management executive with a proven track record in achieving sales objectives in the pharmaceutical industry. Prior to joining, he was Director of Sales at Allergan Pharmaceuticals where he directed and managed an 85 person sales division.

During the search process, there were a total of 79 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Matt will play a leading role in adding to our client’s planned growth and product commercialization activities, providing a vital cornerstone for the Company’s future growth and success. We look forward to the continued success of both Matt and our client.

Vice President of Sales and Marketing

Biocept, Inc.

We are proud to announce the successful completion of Search Assignment # A24601 for a Vice President of Sales and Marketing at Biocept, Inc. Our client is a privately held diagnostics clinical testing services company that is developing a powerful class of diagnostic assays for personalized medicine in early detection, diagnosis, and monitoring of cancer. The Company is in the process of commercializing its first two predictive cancer assays through its certified CLIA laboratory for breast cancer and non-small cell lung cancer.

The successful candidate chosen is Mr. Todd Johnson. He has over 17 years of successful sales and marketing management experience in the diagnostics and clinical testing services industry. Most recently he was Vice President of Sales at Insight Health Corporation. Prior to that he held management positions of increased responsibility at Polymedco, LabCorp, Esoterix, Ventana Medical Systems, and Abbott Laboratories.

Todd will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Todd and our client.

Vice President of Marketing

Inova Diagnostics, Inc.

We are proud to announce the successful completion of Search Assignment # A43401 for a Vice President of Marketing at Inova Diagnostics, Inc., a division of the Werfen Group. Our client is a recognized worldwide leader in autoimmune disease diagnostics. Since its founding in 1987, the Company has consistently delivered the first commercially available or FDA cleared autoimmune diagnostic tests for a variety of diseases. Their founders were directly involved in the development of autoimmune disease serology, responsible for the first commercially available autoantibody test kits.

The successful candidate chosen is Ms. Patricia Swartwood. She has over 20 years of successful marketing management experience in the diagnostics industry. Most recently she was Vice President of Marketing at Cypress Bioscience following the acquisition of Proprius Pharmaceuticals. Prior to that she held management positions of increased responsibility at Prometheus Laboratories, Quest Diagnostics, Dura Pharmaceuticals, and Quidel Corporation.

Patricia will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Patricia and our client.

Senior Vice President of Marketing and Sales

Transgenomic, Inc.

We are proud to announce the successful completion of Search Assignment # A23702 for a Senior Vice President of Marketing and Sales at Transgenomic, Inc. Our publicly held client is developing and commercializing unique instrument systems, reagents, and laboratory testing services to the academic and medical research, clinical, and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis. It currently has an installed base of over 1,200 systems in 35 countries worldwide.

The successful candidate chosen is Mr. Chad Richards. He has over 15 years of senior management experience in the diagnostic and biotechnology industries. Most recently, Chad was the National Sales Director, Cancer Diagnostics Division, for Quest Diagnostics. Previously he held various senior level management positions of increased responsibility at Ventana Medical Systems.

During the search process, there were a total of 48 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Chad will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Chad and our client.

Senior Vice President and Chief Scientific Officer

Optimer Pharmaceuticals, Inc.

We are proud to announce the successful completion of Search Assignment # A24501 for a Senior Vice President and Chief Scientific Officer at Optimer Pharmaceuticals, Inc. Our client is a publicly held biopharmaceutical company engaged in the development and commercialization of anti-infective drugs to address serious infectious diseases. The Company has five drugs in clinical development, two of which are in late stage phase III clinical trials. Their lead drug candidate recently completed a Phase III trial and top line data demonstrated the drug met both primary and secondary endpoints.

The successful candidate chosen is Xavier Frapaise, M.D. Most recently, Xavier served as President and C.E.O. at Asphelia Pharmaceuticals, Inc., where he was responsible for evaluating and in-licensing promising drug candidates, successfully moving them forward in the clinical trial process. During the previous twenty years, he held senior level management positions such as Chief Medical Officer, Corporate V.P. of Research and Development, and Director of Medical Affairs for Ocera Therapeutics, TAP Pharmaceuticals, Abbott Laboratories, and Bayer Pharmaceuticals.

During the search process, there were a total of 61 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Xavier will play a leading role in our client’s future clinical, research, and product commercialization programs. We look forward to the continued success of both Xavier and our client.

Vice President of Operations

Inova Diagnostics, Inc.

We are proud to announce the successful completion of Search Assignment # A43404 for a Vice President of Operations at Inova Diagnostics, Inc., a division of the Werfen Group. Our client is a recognized worldwide leader in autoimmune disease diagnostics. Since its founding in 1987, the Company has consistently delivered the first commercially available or FDA cleared autoimmune diagnostic tests for a variety of diseases. Their founders were directly involved in the development of autoimmune disease serology, responsible for the first commercially available autoantibody test kits.

The successful candidate chosen is Mr. Abe Chohan. He has almost 20 years of successful operational and manufacturing management experience in the diagnostics industry. Most recently he was Director of manufacturing and Quality Engineering at Quidel Corporation. Prior to that he held management positions of increased responsibility at GKN Chem-tronics, Eastman Chemical Company, and FMC Corporation.

Abe will play a leading role in our client’s future growth. We look forward to the continued success of both Abe and our client.

Director of Research and Development

Inova Diagnostics, Inc.

We are proud to announce the successful completion of Search Assignment # A43405 for a Director of Research and Development at Inova Diagnostics, Inc., a division of the Werfen Group. Our client is a recognized worldwide leader in autoimmune disease diagnostics. Since its founding in 1987, the Company has consistently delivered the first commercially available or FDA cleared autoimmune diagnostic tests for a variety of diseases. Their founders were directly involved in the development of autoimmune disease serology, responsible for the first commercially available autoantibody test kits.

The successful candidate chosen is Gabriella Lakos, M.D., Ph.D. She has over 16 years of research and development experience in the diagnostics industry. Most recently she was Director of Research and Development at TheraTest Laboratories, Inc. where she was responsible for the complete development of Invitro diagnostic immunoassays from concept through to commercialization, including managing 510(k) submissions to the FDA and a CLIA Reference Laboratory. Prior to that, she spent 12 years as Associate Professor and Director of Clinical Immunology at the University of Debrecen Medical School.

Gabriella will play a leading role in our client’s future growth. We look forward to the continued success of both Gabriella and our client.

Director of Regulatory Affairs and Quality Assurance

Hitachi America Ltd.

We are proud to announce the successful completion of Search Assignment # A43901 for a Director of Regulatory Affairs and Quality Assurance for Hitachi Diagnostics, Inc.

Our Client is a global leader of in vitro allergy diagnostics with a legacy of innovation. It was the first company to introduce a multiple in vitro diagnostic test for allergies and one of the first to introduce a chemiluminescent assay system for the detection of IgE antibodies. The Company holds numerous in vitro allergy testing technology patents and continues to pioneer advancements in the field.

The successful candidate chosen is Ms. Lisa Charter. Lisa has over 13 years of combined experience in regulatory affairs, research, and development in the areas of IVD drug monitoring, toxicology, and anatomical pathology with companies such as Microgenics Corporation and most recently with the Thermo Fisher Scientific Clinical Diagnostic Division. Her professional strengths are in the areas of 510 (k)’s for Class I and Class II IDV’s, European CE Marking, Design Dossiers 21, CFR 820, ISO 13485, Design, Control and Commercialization, and regulatory audits and inspections.

Lisa will play a leading role in our client’s future growth. We look forward to the continued success of both Lisa and our client.

Vice President of Marketing and Sales

Hunter Laboratories, Inc.

We are proud to announce the successful completion of Search Assignment # A43801 for a Vice President of Marketing and Sales at Hunter Laboratories, Inc.

Our client is the largest locally owned and operated clinical reference laboratory in Northern California. It is a recognized industry leader that offers a comprehensive array of laboratory tests, including advanced new tests, treatment algorithms, sophisticated risk characterization, and personalized therapy guidelines in areas ranging from cardiovascular to cancer screening to assist physicians in diagnosis and treatment.

The successful candidate chosen is Mr. Philip Gateley. He has over 15 years of sales and marketing management experience in the diagnostics industry. Most recently he was the Cardiopulmonary Specialist for Strategic accounts at United Therapeutics. Previously, he held positions in various sales and sales management positions of increased responsibility at Berkeley HeartLab, Sepracor Pharmaceuticals, Kos Pharmaceuticals, and Sanofi-Synthelabo.

Philip will play a leading role in our client’s future growth. We look forward to the continued success of both Philip and our client.

Vice President of Sales

Inova Diagnostics, Inc.

We are proud to announce the successful completion of Search Assignment # A43406 for a Vice President of Sales at Inova Diagnostics, Inc., a division of the Werfen Group. Our client is a recognized worldwide leader in autoimmune disease diagnostics. Since its founding in 1987, the Company has consistently delivered the first commercially available or FDA cleared autoimmune diagnostic tests for a variety of diseases. Their founders were directly involved in the development of autoimmune disease serology, responsible for the first commercially available autoantibody test kits.

The successful candidate chosen is Mr. Bryan Hoenig. He has over 15 years of sales and sales management experience in the diagnostics industry. Most recently he was Senior Director of Sales at Siemens Healthcare Diagnostics where he was responsible for a $415 MM instrument and reagent business. Prior to that, he spent 9 years in various sales and sales management positions of increased responsibility at Abbott Laboratories Diagnostics Division.

Bryan will play a leading role in our client’s future growth. We look forward to the continued success of both Bryan and our client.

Senior Director of Assay Development

Roka Bioscience, Inc.

We are proud to announce the successful completion of Search Assignment # A24801 for a Senior Director of Assay Development at Roka Bioscience, Inc., a spin-off of Gen-Probe, Inc. Our client develops rapid, highly accurate molecular diagnostic assays and instrument systems for biopharmaceutical manufacturing, water, and food safety testing industries. The Company was established in 2009 through a spin-off of Gen-Probe’s industrial nucleic acid testing assets, technology, and its Closed Unit Dose Assay (CUDA) fully integrated instrument platforms by an exclusive license. The Company recently introduced its first highly accurate molecular assays for the detection of Listeria and Salmonella.

The successful candidate chosen is Ming-Chou Lee, Ph.D. He has over 20 years of research and assay development experience in the diagnostics industry. Most recently he was Vice President of Assay Development at PrimeraDx, Inc. where he was responsible for the development of molecular assays and instrument platforms, including managing 510(k) submissions to the FDA. Prior to that, he spent six years as Director of R&D at Focus Diagnostics. Previously he spent 10 years with Beckman Coulter developing various genetic analysis products.

Ming will play a leading role in our client’s future growth. We look forward to the continued success of both Ming and our client.

Member of the Board of Directors

Transgenomic, Inc.

We are proud to announce the successful completion of Search Assignment # A23704 for a Member of the Board of Directors at Transgenomic, Inc. Our publicly held client has developed and commercialized unique laboratory testing services, instrument systems, and reagents to the academic, medical research, clinical, and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis in the fields of pharmacogenomics and personalized medicine.

The successful candidate chosen is Antonius Schuh, Ph.D. Presently Toni serves as Chairman and CEO of Sorrento Therapeutics, Inc. (STI), a biotechnology company built on a proprietary antibody library construction technology. Prior to STI, Dr. Schuh was the Founding Chief Executive Officer and Director of AviaraDx, Inc., a molecular diagnostics laboratory company focused on oncology testing which was acquired by bioMerieux. Before leading AviaraDx, Dr. Schuh was Chief Executive Officer of Arcturus Bioscience, Inc. and Sequenom, Inc.

Toni will play a leading role in our client’s future growth. We look forward to the continued success of both Toni and our client.

Director of Regulatory Affairs and Quality Assurance

Diadexus, Inc.

We are proud to announce the successful completion of Search Assignment # A42208 for a Director of Regulatory Affairs and Quality Assurance at Diadexus, Inc. Our client is a privately held biotechnology company engaged in the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The Company’s lead product, the PLAC^® Test, is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

The successful candidate chosen is Ms. Lynne McBride. She has over 20 years of successful management experience in regulatory affairs and quality assurance in the biotechnology industry. Most recently, Lynne served as Director of Regulatory Affairs at Genomic Health. Prior to that, she held senior regulatory management positions of increased responsibilities at BD Biosciences and Beckman Coulter.

During the search process, there were a total of 100 candidates screened. The search was narrowed to three semifinalists, prior to final offer and acceptance. Lynne will play a leading role in our client’s future growth and product commercialization programs. We look forward to the continued success of both Lynne and our client.

Vice President of Finance

Mannkind Corporation

We are proud to announce the successful completion of Search Assignment # A22302 for a Vice President of Finance at MannKind Corporation. Our publicly held biopharmaceutical client is focused on the development and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, a proprietary inhaled insulin system for the treatment of diabetes, is currently in late stage phase 3 clinical trials in the U.S. and Europe. Our client has raised in excess of one billion dollars from private and public rounds of financing over the last seven years and currently has over 500 employees.

The successful candidate chosen is Mr. Frank Hudson. He has over 20 years of financial management experience in the pharmaceutical industry. Most recently, Frank was Vice President of Finance at GlaxoSmithKline, a multi-billion dollar pharmaceutical company, where he held various financial management positions of increased responsibility for the last 15 years. Prior to this he held various finance positions at Eli Lilly and Company.

During the search process, there were a total of 93 candidates screened. The search was narrowed to four semifinalists, prior to final offer and acceptance. Frank will play a leading role in our client’s future growth and commercialization programs. We look forward to the continued success of both Frank and our client.

Senior Vice President and Chief Financial Officer

Clarient, Inc.

We are proud to announce the successful completion of Search Assignment # A23401 for a Senior Vice President and Chief Financial Officer at Clarient, Inc. Our Southern California based client is a comprehensive cancer services company and a growing leader in advanced cancer diagnostics. It provides innovative technologies, services, and support for the characterization, assessment, and treatment of cancer, improving quality of life, reducing patient care costs, and accelerating the drug development process. Its services are currently sold worldwide to clinical laboratories, hospitals, university medical centers, and biopharmaceutical companies.

The successful candidate chosen is Mr. James Agnello. He brings over 15 years of experience in the laboratory services business. Recently he served as Divisional Chief Financial Officer at Teleflex, a $2.5 billion global manufacturing conglomerate. Prior to this, Jim served as Senior Vice President and Chief Financial Officer for Impath, Inc., a science-based health care services company, and as Vice President and Controller for SmithKline Beecham’s $1.5 billion clinical laboratory division prior to its merger with Quest Diagnostics.

During the search process, there were a total of 148 candidates screened. The search was narrowed to five semifinalists, prior to final offer and acceptance. Jim will play a leading role in adding to our client’s planned growth and product commercialization activities, providing a vital cornerstone for the Company’s future growth and success. We look forward to the continued success of both Jim and our client.

Vice President of Sales

Althea Technologies

We are proud to announce the successful completion of Search Assignment # A24301 for a Vice President of Sales at Althea Technologies, Inc. Our client is a global provider of a wide range of contract services to the biotechnology and pharmaceutical industry including cGMP manufacturing of products from Phase I through to commercial API production, aseptic fill and finish, gene expression analysis for target validation and lead compound selection, custom real-time qPCR, and assay development services.

The successful candidate chosen is Mr. Cory Lewis. Most recently, Cory served as Director of Global New Business Development at Baxter BioPharma Solutions, a division of Baxter Healthcare Corporation, where he directed all new business development and revenue generating programs for a $200 million division. Previously, he held various senior level management positions of increased responsibility for ten years at Baxter Healthcare Corporation.

During the search process, there were a total of 61 candidates screened. The search was narrowed to two semifinalists, prior to final offer and acceptance. Cory will play a leading role in our client’s future growth and expansion programs. We look forward to the continued success of both Cory and our client.